HeartBeam Reports Third Quarter 2026 Financial and Operational Results
HeartBeam, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its strategic focus on heart attack assessment.
Stocks · News reference
HeartBeam, Inc. has successfully completed patient enrollment for its 486-patient HEADSTART-ACS study ahead of the original schedule.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HeartBeam, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its strategic focus on heart attack assessment.
HeartBeam, Inc. announced it will host a conference call to discuss its third quarter 2026 financial results on November 12, 2026.
HeartBeam reported positive results from a pilot study presented at the TCT 2026 conference, demonstrating that its patient-recorded 3D ECG technology is as accurate as a standard 12-lead ECG.
HeartBeam, Inc. announced it will present the results of its ALIGN-ACS study, which evaluates the company's technology for heart attack assessment, at the TCT 2026 conference on November 1, 2026.
HeartBeam, Inc. has received U.S. Food and Drug Administration (FDA) clearance for its technology designed to assess acute myocardial infarction.
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is